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Abstract
Interferon-inducible transmembrane proteins 1, 2, and 3 (IFITM1, 2, and 3) are recently identified viral restriction factors that
inhibit infection mediated by the influenza A virus (IAV) hemagglutinin (HA) protein. Here we show that IFITM proteins
restricted infection mediated by the entry glycoproteins (GP1,2) of Marburg and Ebola filoviruses (MARV, EBOV). Consistent
with these observations, interferon-b specifically restricted filovirus and IAV entry processes. IFITM proteins also inhibited
replication of infectious MARV and EBOV. We observed distinct patterns of IFITM-mediated restriction: compared with IAV,
the entry processes of MARV and EBOV were less restricted by IFITM3, but more restricted by IFITM1. Moreover, murine
Ifitm5 and 6 did not restrict IAV, but efficiently inhibited filovirus entry. We further demonstrate that replication of infectious
SARS coronavirus (SARS-CoV) and entry mediated by the SARS-CoV spike (S) protein are restricted by IFITM proteins. The
profile of IFITM-mediated restriction of SARS-CoV was more similar to that of filoviruses than to IAV. Trypsin treatment of
receptor-associated SARS-CoV pseudovirions, which bypasses their dependence on lysosomal cathepsin L, also bypassed
IFITM-mediated restriction. However, IFITM proteins did not reduce cellular cathepsin activity or limit access of virions to
acidic intracellular compartments. Our data indicate that IFITM-mediated restriction is localized to a late stage in the
endocytic pathway. They further show that IFITM proteins differentially restrict the entry of a broad range of enveloped
viruses, and modulate cellular tropism independently of viral receptor expression.
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Introduction
The interferon-inducible transmembrane (IFITM) proteins are
a family of viral restriction factors that play critical roles in the
interferon-mediated control of influenza A virus (IAV) [1]. These
proteins inhibit both IAV replication and infection by hemagglu-
tinin (HA)-pseudotyped retroviruses, indicating that they target the
IAV entry process. IFITM proteins also restrict an early step in the
lifecycle of several flaviviruses, including dengue and West Nile
viruses. In contrast, they do not inhibit replication of murine
leukemia virus (MLV), or the entry processes of amphotropic
MLV, Machupo virus (MACV), Lassa virus (LASV), or lympho-
cytic choriomeningitis virus (LCMV). Although IFITM proteins
are induced by type I and II interferons, most cells and cell lines
express a basal level of one or more of these proteins [2]. IFITM1,
2, and 3 are expressed in a wide range of tissues, whereas IFITM5
expression appears to be limited to bone [3]. Mice have orthologs
for IFITM1, 2, 3, and 5, as well as two additional IFITM genes,
Ifitm6 and Ifitm7. IFITM4P is a pseudogene in both species [4].
Two IFITM proteins have been identified in chickens, orthologs of
human IFITM1 and IFITM5. The IFITM proteins are small
(,130 amino acids), with two transmembrane domains separated
by a highly conserved cytoplasmic domain. Both amino- and
carboxy- domains are luminal [5].
Enveloped viruses usually express surface proteins that mediate
attachment of virions to a cellular receptor. Following receptor
PLoS Pathogens | www.plospathogens.org 1 January 2011 | Volume 7 | Issue 1 | e1001258engagement, these entry proteins undergo conformational changes
that ultimately promote mixing of viral and cellular membrane
lipids, formation of a fusion pore, and transfer of the viral genome
to the cell cytoplasm [6]. The conformational changes of some
entry proteins, for example IAV HA or flavivirus E proteins, are
induced by low pH [7,8]. Fusion mediated by these proteins
requires access to an acidic cellular compartment such as a late
endosome or lysosome. In contrast, other entry proteins such as
the envelope proteins of HIV-1 and MLV do not require access to
an acidic compartment, and these viruses are presumed to fuse at
the plasma membrane or in an early endocytic vesicle [9]. Finally,
some entry proteins, such as the severe acute respiratory syndrome
coronavirus (SARS-CoV) spike (S) protein or the filovirus
glycoproteins (GP1,2), indirectly require low pH to activate
target-cell proteases necessary for viral entry [10,11,12,13].
Proteolytic cleavage of these entry proteins by lysosomal cathepsin
L (SARS-CoV) or cathepsins B and L (Ebola virus; EBOV)
promotes the final steps of viral fusion [14,15]. In the case of
SARS-CoV, the requirement for cathepsin L can be circumvented
by treatment of receptor-bound virions with trypsin or related
proteases [16]. This observation has been used to suggest
alternative pathways for SARS-CoV infection, depending on
whether cathepsin L or an extracellular protease activates the
receptor-associated S protein.
Here we demonstrate that, like IAV, the entry processes of
Marburg virus (MARV), EBOV, and SARS-CoV are specifically
restricted by IFITM proteins. We observed that various human,
mouse, and chicken IFITM orthologs differentially restricted IAV
and filoviruses. We further showed that restriction of SARS-CoV
was circumvented by trypsin treatment of cell-associated virions.
Our data identify variation in the properties of individual IFITM
proteins and localize their restriction activity to a late stage in the
endocytic pathway. They further suggest that these proteins
restrict a broad range of enveloped viruses, and can modulate
cellular tropism independently of viral receptor expression.
Results
MARV and EBOV GP1,2-mediated entry is restricted by
IFITM1, 2, and 3
The IFITM proteins restrict IAV HA-mediated entry, and an
early stage in the replication of several flaviviruses [1]. The entry
process of each of these viruses is pH dependent. We sought to
determine if additional viruses that require access to late endocytic
or lysosomal compartments were similarly restricted by these
proteins. The entry processes of MARV and EBOV require
activation by one or more cathepsins, whose activity is localized to
lysosomes [10,12,13,17]. Both EBOV and MARV require
cathepsin L activity to infect cells, whereas EBOV also requires
cathepsin B activity [10,12,13]. Accordingly, we incubated MLV-
based pseudoviruses bearing the entry proteins of MARV, EBOV,
H5 or H7 IAV, MLV, or MACV with A549 lung epithelial cells
transduced to express human IFITM1, 2 or 3, or with vector alone
[18,19,20]. As we have previously reported [1], infection mediated
by the entry proteins of MLV or MACV was unaffected by the
presence of IFITM proteins (Fig. 1A), despite their efficient
expression (Fig. 1B). In contrast, as reported, IAV HA-mediated
entry was markedly inhibited by the same proteins. Similarly, we
observed that entry mediated by MARV and EBOV GP1,2
proteins was inhibited by IFITM1, 2 and 3 (Figs. 1A and S1A).
Comparable results were obtained in Vero E6 cells, an African
green monkey kidney epithelial cell line and the standard cell line
for laboratory propagation of these viruses (Figs. 1C and D), and
for human umbilical vein endothelial cells (HUVEC), a primary
cell target of filovirus infection (Figs. 1E and F). We have
repeatedly observed that IFITM-mediated restriction is less
efficient in human embryonic kidney 293T cells. Consistent with
this observation, both IAV HA- and filovirus GP1,2-mediated
entry were only partially suppressed in these cells, whereas control
pseudoviruses remained unaffected (Figs. 1G and H). Our data
indicate that IFITM1, 2, and 3 each restrict MARV and EBOV
GP1,2-mediated entry, and identify cell-type differences in the
efficiency of restriction. We speculate that these differences arise
from expression differences of necessary restriction cofactors or
proteins that interfere with IFITM protein activity.
Type 1 interferon inhibits filovirus GP1,2-mediated entry
Expression of IFITM proteins is potently induced by type I or
type II interferons (Fig. S1B) [2]. To determine whether the entry
processes of MARV and EBOV are similarly regulated by type I
IFN, we incubated HeLa cells with IFN-b and then infected cells
with pseudoviruses bearing MARV, EBOV, IAV, MACV, or
MLV entry proteins (Fig. 1I). As has been previously reported,
IFN-b treatment upregulated IFITM proteins (Fig. 1J). Consistent
with this higher expression of IFITM proteins, entry mediated by
MARV and EBOV GP1,2 or IAV HA was markedly inhibited by
IFN-b (Fig. 1I). In contrast, infection by MLV and MACV
pseudoviruses was only modestly suppressed, an effect possibly due
to post-entry inhibition of GFP expression in treated cells. We
conclude that that the entry processes of MARV, EBOV, and IAV
are inhibited by type I IFN.
Replication of infectious MARV and EBOV is restricted by
IFITM1, 2, and 3
To determine whether IFITM proteins restrict infectious
filoviruses, Vero E6 cells transduced to express IFITM1, 2 or 3,
or with vector alone were incubated with infectious MARV or
EBOV at MOIs of 1 or 15. As was observed with pseudoviruses,
replication of both infectious filoviruses was restricted by expression
of IFITM proteins (Figs. 2A–C and S1C), most consistently by
Author Summary
Cells express restriction factors, proteins whose primary
activity is to inhibit viral replication. We have recently
described a family of restriction factors, interferon-induc-
ible transmembrane (IFITM) proteins, that interfere with
replication of influenza A virus. The IFITM proteins
uniquely inhibit replication early in the viral life-cycle,
before the virus can successfully enter the cell cytoplasm.
Here we show that the entry processes of several highly
pathogenic viruses – Marburg virus, Ebola virus, and SARS
coronavirus – are similarly disrupted by IFITM proteins. We
compared IFITM-mediated restriction of these viruses with
influenza A virus, and discovered that individual IFITM
proteins are specialized for restriction. For example, we
describe two mouse IFITM proteins that efficiently restrict
entry of Marburg and Ebola viruses, but which do not
inhibit influenza A virus. We further show that we can
circumvent IFITM-mediated restriction by inducing a virus
to enter a cell at or near the plasma membrane. This
observation indicates that restriction is not a global
property of the cell, but rather is localized to late
endosomal and lysosomal compartments, the usual entry
sites of IFITM-restricted viruses. This study therefore
enhances our understanding of how the innate immune
system controls influenza A virus and other pathogenic
viruses.
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Thus expression of IFITM1, 2, or 3 suppresses replication of
infectious MARV and EBOV. Collectively with Fig. 1, these data
suggest that suppression of filovirus replication by IFITM proteins
and by type I interferons is due in part to inhibition of entry.
SARS-CoV S protein mediated entry is restricted by
IFITM1, 2, and 3
As is the case for both MARV and EBOV, SARS-CoV requires
cathepsin L activity to enter cells [10,11]. We therefore
investigated whether IFITM proteins could restrict SARS-CoV
Figure 2. Replication of infectious MARV and EBOV is restricted by IFITM1, 2, and 3. Vero E6 cells transduced to express the indicated c-
myc-tagged IFITM proteins or with vector alone were incubated with infectious (A) MARV or (B) EBOV at indicated MOIs for 1 hour and then
maintained in growth medium. After 72 hours, culture supernatant was harvested and viral titer was assayed using quantitative RT-PCR. A single
asterisk indicates a significant difference with controls cells (P,0.05); double asterisks indicate P,0.1. (C) IFITM protein expression in Vero E6 cells was
assayed by western blot using anti-c-myc antibody. (D) and (E) are experiments similar to those in (A) and (B), except A549 cells transduced to
express the indicated c-myc-tagged IFITM proteins or with vector alone were used. (F) IFITM protein expression in A549 cells was assayed by western
blot using anti-c-myc antibody. Each panel represents two experiments with similar results.
doi:10.1371/journal.ppat.1001258.g002
Figure 1. MARV and EBOV GP1,2-mediated entry is restricted by IFITM1, 2, and 3. (A) A549, (C) Vero E6, (E) HUVEC, or (G) 293T cells
transduced to express the indicated c-myc-tagged IFITM proteins or with vector alone were infected with MLV-GFP pseudotyped with the entry
proteins of EBOV, MARV, IAV, MLV, or MACV, as indicated. Two days later, pseudovirus infection was determined by flow cytometry. Relative
infectivity represents the percentage of GFP-positive cells, normalized to that of cells transduced with vector alone. Numbers underneath figures
indicate percentage of infected cells in vector-transduced cells. Differences in pseudovirus entry between vector alone and IFITM expressing cells are
significant (P,0.05) for all MARV, EBOV, IAV pseudoviruses excepting H7(FPV) in 293T cells expressing IFITM1 (P,0.1). IFITM protein expression in (B)
A549, (D) Vero E6, (F) HUVEC, or (H) 293T cells was measured by western blot with an anti-c-myc antibody (9E10), using aliquots of the same cells
assayed in (A), (C), (E), and (G), respectively. b-actin was included as a loading control. (I) Experiment similar to (A) except that HeLa cells were treated
with 5000 U/ml IFN-b or maintained in growth medium for 48 hours before infection with the indicated pseudoviruses. Differences in pseudovirus
entry between MLV or MACV and MARV, EBOV, or IAV are statistically significant (P,0.05), as are all differences in pseudovirus entry between IFN-b-
treated and untreated cells. (J) In parallel, aliquots of the same cells assayed in (I) were used to determine the expression of IFITM proteins. IFITM
proteins were analyzed by western blot and probed with the indicated anti-IFITM1 or anti-IFITM2/3 antibody. Each panel of the figure represents at
least three experiments with similar results.
doi:10.1371/journal.ppat.1001258.g001
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CoV receptor, angiotensin-converting enzyme 2 (ACE2), into
A549 cells before transducing them to express IFITM1, 2, or 3, or
with vector alone [21]. Entry mediated by the SARS-CoV S
protein, like IAV HA-mediated entry, was restricted by each
IFITM protein, whereas MLV and MACV pseudoviruses were
unaffected (Fig. 3A). IFITM expression did not substantially
interfere with cell-surface expression of ACE2, indicating that
suppression is not due to receptor down-regulation (Fig. 3B and
C). Similar results were obtained in Vero E6 cells (Figs. 3D, E, and
F). Consistent with SARS-CoV pseudoviruses, infectious SARS-
CoV replicated in control Vero cells markedly more efficiently
than in cells expressing IFITM1, 2, or 3 (Figs. 3G and H). We
conclude that, like EBOV and MARV, SARS-CoV entry can be
restricted by each IFITM.
Depletion of IFITM proteins differentially enhances
infection mediated by MARV, SARS-CoV, and IAV entry
proteins
Throughout our studies we observed a modest trend in cells
over-expressing IFITM proteins in which IFITM3 more efficiently
restricted IAV [1], whereas no similar pattern was observed with
MARV, EBOV, or SARS-CoV. To further explore differences
HeLa cells were transduced to express shRNA targeting IFITM1,
2, 3 or shRNA targeting both IFITM1 and 3 expression. Cells
Figure 3. SARS-CoV S infection is restricted by IFITM1, 2, and 3. (A) A549 or (D) Vero E6 cells transduced to express ACE2 were subsequently
transduced to express the indicated c-myc-tagged IFITM proteins or with vector alone. Two days later, cells were infected with indicated
pseudoviruses. Pseudovirus infection was determined by flow cytometry, and normalized to that of cells transduced with vector alone. Differences in
pseudovirus entry between vector alone and IFITM expressing cells are significant (P,0.05) for all SARS-CoV and IAV pseudoviruses. In parallel, cell-
surface expression of ACE2 was assayed using aliquots of the same (B) A549 or (E) Vero E6 cells analyzed in (A) and (D), respectively. Cells were
labeled with Alexa-488 conjugated S protein RBD of SARS-CoV and analyzed by flow cytometry. ACE2 expression is shown as mean fluorescence
intensity. Expression of c-myc-tagged IFITM proteins was assayed by western blot using aliquots of the same (C) A549 or (F) Vero E6 cells analyzed in
(A) and (D), respectively. Each panel represents at least three experiments with similar results. (G) Vero cells transduced to express indicated c-myc-
tagged IFITM proteins or with vector alone were incubated in duplicate with infectious SARS-CoV at a MOI of 0.1 for 1 hour. Supernatants were
harvested 1, 6, 12, 18, 24, or 30 hours later and viral titers were measured by plaque assay. (H) Expression of c-myc-tagged IFITM proteins was assayed
by western blot using aliquots of cells analyzed in (G).
doi:10.1371/journal.ppat.1001258.g003
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incubated with MARV, EBOV, IAV, MLV or MACV pseudo-
viruses (Figs. 4A and B). As expected, IFN-b efficiently inhibited
entry mediated by MARV and EBOV GP1,2 and IAV HA
proteins. Depletion of IFITM3 fully restored IAV HA-mediated
infection, an effect only modestly enhanced through suppression of
IFITM1 expression. In contrast, entry mediated by MARV and
EBOV GP1,2 was not restored in cells expressing shRNA targeting
IFITM1 or IFITM3 expression. However, when both IFITM1
and IFITM3 were depleted, filovirus GP1,2-mediated entry was
partially restored. These results suggest that IAV entry is more
sensitive to IFITM3-mediated restriction whereas IFITM1 plays a
more important role in suppressing filovirus entry processes.
We further examined these differing profiles of IFITM
restriction in cells endogenously expressing IFITM proteins. HeLa
cells express a detectable basal level of IFITM3, but not IFITM1
(Fig. 4A). shRNA targeting IFITM3 markedly enhanced entry
mediated by all four IAV HA proteins assayed, but did not
substantially increase infection by MARV, EBOV, or control
pseudoviruses (Fig. 4C and Fig. S2A). Similarly IFITM-targeting
shRNA did not affect entry of SARS-CoV pseudovirus into
ACE2-expressing HeLa cells, whereas IAV infection was again
markedly enhanced by IFITM3 shRNA (Fig. 4D). ACE2
expression was comparable in control and IFITM3-depleted cells
(Fig. S2B). To explore the role of endogenous IFITM1, we used
human myelogenous leukemia K562 cells, which express relatively
Figure 4. Depletion of IFITM proteins differentially enhances infection mediated by MARV, EBOV, SARS-CoV, and IAV entry
proteins. (A) HeLa cells were transduced to express control shRNA or shRNA targeting IFITM1, 2, 3, or IFITM1 and 3 (IFTIM1/3), and selected by
puromycin. HeLa cells were then treated with 1000 U/ml IFN-b or with medium alone for 48 hours. Expression of IFITM proteins in control or IFITM
depleted HeLa cells was assayed by western blot using the indicated anti-IFITM1 or anti-IFITM2/3 antibody. b-actin was included as a loading control.
(B) Aliquots of the cells used in (A) were infected with MLV-GFP pseudotyped with the indicated entry proteins. Pseudovirus infection was measured
by flow cytometry, and normalized to infection of cells expressing control shRNA in the absence of IFN-b. Differences in pseudovirus entry between
IFN-b-treated and untreated cells for MARV, EBOV, or IAV are significant (P,0.05), except for IAV entry into HeLa cells expressing IFITM3 or IFITM1/3
shRNA. (C) Experiment similar to (B) except HeLa cells stably expressing indicated shRNA were assayed in the absence of IFN-b.( D) HeLa cells
expressing indicated shRNA were transduced to express ACE2 and infected with indicated pseudoviruses. Differences in pseudovirus entry between
cells expressing control and IFITM3 shRNA in (C) and (D) are significant (P,0.05) for IAV pseudoviruses only. (E) Experiment similar to (A) except that
K562 cells were transduced to express control shRNA or shRNA targeting IFITM1, and selected by puromycin. (F) Experiment similar to that in (B)
except that infectivity of the indicated pseudoviruses was measured in K562 cells stably expressing the indicated shRNA. (G) Experiment similar to (D)
except that infectivity of the indicated pseudoviruses was measured in ACE2- and shRNA-expressing K562 cells. Differences in pseudovirus entry
between cells expressing control and IFITM1 shRNA in (F) and (G) were significant (P,0.05) for MARV, SARS-CoV, and IAV pseudoviruses. Each panel
of the figure represents at least two experiments with similar results.
doi:10.1371/journal.ppat.1001258.g004
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markedly enhanced entry of MARV and, to a lesser extent, IAV
pseudoviruses (Fig. 4F). Similarly, shRNA targeting IFITM1 did
not alter ACE2 expression, but enhanced SARS-CoV S protein-
mediated entry (Figs. 4G and S2C). Thus, cells can express
different basal levels of each IFITM protein, and these levels
differentially alter their susceptibility to IAV and cathepsin-
dependent viruses.
Murine and chicken IFITM orthologs differentially restrict
infection mediated by MARV, EBOV, and IAV entry
proteins
To further explore the extent to which IFITM proteins
differentially restrict IAV and filoviruses, A549 cells were
transduced to express all known human (Figs. 5A and B), mouse
(Figs. 5C and D), or chicken (Figs. 5E and F) IFITM orthologs.
Cells were then incubated with pseudoviruses bearing MARV,
EBOV, IAV, MLV, or MACV entry proteins. Nearly every
IFITM ortholog restricted MARV and EBOV GP1,2-mediated
entry, despite variation in the expression of these orthologs. Note
that human IFITM5 expression, undetectable by western blotting,
was observed by immunofluorescent staining (Fig. S3D). In
contrast, mouse and chicken IFITM5 and mouse IFITM6 did
not efficiently restrict IAV HA-mediated entry. (An alignment of
IFITM orthologs is shown in Fig. S3). Unlike the modest
differences between human IFITM1 and IFITM3, these differ-
ences were sufficient to be observed in over-expression assays. We
conclude that IFITM genes have overlapping but distinct effects
on the entry of IAV and filoviruses.
Figure 5. Murine and chicken IFITM orthologs differentially restrict infection mediated by MARV, EBOV, and IAV entry proteins.
A549 cells were transduced to express the indicated c-myc-tagged (A) human, (C) mouse, or (E) chicken IFITM orthologs. Two days later, cells were
infected with MLV-GFP pseudotyped with the indicated viral entry glycoproteins. Pseudovirus infection was measured by flow cytometry, and
normalized to that of cells transduced with vector alone. Expression of (B) human, (D) mouse, or (F) chicken IFITM protein orthologs in A549 cells
assayed in (A), (C), and (E), respectively was measured by western blot using the anti-c-myc antibody (9E10). All differences in pseudovirus entry
between control and IFITM-expressing cells are significant (P,0.05) except for H5(Thai) entry into murine Ifitm6- and chicken Ifitm5-expressing
cells, and for H7(FPV) entry into murine Ifitm1- and Ifitm5-expressing cells. Each panel of the figure represents at least two experiments with similar
results.
doi:10.1371/journal.ppat.1001258.g005
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mediated by SARS-CoV S protein
Previous studies have shown that the cathepsin L dependence of
SARS-CoV can be bypassed by addition of exogenous trypsin to
ACE2-bound virions or pseudovirions, likely by inducing S-
protein-mediated fusion at or near the plasma membrane [11,16].
In contrast to cathepsin L-mediated fusion, exogenous trypsin
promotes fusion at or near the plasma membrane. To localize
IFITM-mediated restriction, we investigated the effect of trypsin
treatment on SARS-CoV entry into IFITM-expressing cells. Vero
E6 cells transduced to express ACE2 and IFITM1, 2 or 3, or with
vector alone were incubated with SARS-CoV or MACV
pseudoviruses. As expected, IFITM expression restricted SARS-
CoV S protein-mediated entry, but not MACV GPC-mediated
entry. In contrast, when SARS-CoV pseudovirions were bound to
ACE2-expressing cells at 4uC and then incubated with trypsin at
37uC for a short time, entry into IFTIM-expressing cells was
largely restored (Figs. 6A, B, and C). These data suggest that
IFITM proteins restrict cathepsin-dependent entry of SARS-CoV
in the lysosome, but cannot restrict trypsin-induced fusion at or
near the plasma membrane. We did not observe in IFITM-
expressing cells any decrease in cellular cathepsin activity that
could readily account for this difference (Figs. 6D and E). These
data show that IFITM-mediated restriction is not a consequence
of a decrease in the activity of lysosomal cathepsins, and suggest
that lysosomal pH, which activates cathepsins B and L, is similarly
unaffected by IFITM protein expression.
IFITM proteins do not interfere with virion access to
acidic cellular compartments
The ability to circumvent IFITM-mediated restriction by
bypassing the requirement for lysosomal cathespins raised the
possibility that IFITM proteins interfere with access of virions to
acidic cellular compartments. Using confocal microscopy, we
monitored infectious IAV virions at 40, 70, and 100 minutes after
association of virions with the plasma membrane in Vero E6 cells
transduced to express IFITM1, 2, or 3, or with vector alone [22]
(Figs. 7 and S4A). In all cases, labeled virions readily colocalized
Figure 6. Trypsin treatment bypasses IFITM restriction of entry mediated by SARS-CoV S protein. (A) Vero E6 cells transduced to express
the indicated c-myc-tagged IFITM proteins or with vector alone were subsequently transduced to express ACE2. Two days later, cells were spin-
inoculated at 4uC with indicated pseudoviruses and then treated with 5 mg/ml trypsin or phosphate-buffered saline (PBS) at 37uC for 13 minutes.
Infected cells were maintained in growth medium and pseudovirus infection was determined by flow cytometry two days later. Relative infectivity
was shown as the percentage of GFP-positive cells, normalized to that of cells transduced with vector alone and treated with PBS. Differences in
SARS-CoV pseudovirus entry between trypsin-treated and untreated cells are significant (P,0.5) for all IFITM-expressing cells. (B) In parallel, ACE2 cell-
surface expression was measured on aliquots of Vero E6 cells used in (A). Vero E6 cells were labeled with Alexa 488-conjugated S-protein RBD of
SARS-CoV and analyzed by flow cytometry. (C) IFITM protein expression in ACE2-expressing Vero E6 cells was measured by western blot with an anti-
c-myc antibody (9E10), using aliquots of the same cells assayed in (A). Figs. (A)–(C) are representative of three experiments with similar results. (D)
Cathepsin L activity in Vero E6 cells transduced with vector alone or stably expressing indicated IFITM proteins was measured fluorometrically and is
shown as mean fluorescence. Cells treated with a cathepsin L inhibitor were used as a control. No statistically significant differences were observed
between vector-transduced and IFITM-expressing cells. (E) Vero E6 cells transduced with vector alone or stably expressing the indicated IFITM
proteins were labeled with MR-(FR)2 or with MR-(RR)2, which bind to the active forms of cathepsin L or B, respectively. Cells were labeled for 1 hour,
fixed with formaldehyde, and analyzed by flow cytometry. In vector-transduced cells, mean fluorescence for MR-(FR)2 was 1175.7 and for MR-(RR)2
was 454.7. The modest enhancement for cathepsin B activity in IFITM2 and 3 expressing cells is significant (P,0.05), whereas no significant
differences were observed in cathepsin L activity. Experiments in (D) and (E) are representative of two experiments with similar results.
doi:10.1371/journal.ppat.1001258.g006
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cent indicator of acidic compartments. In contrast, pretreatment of
cells with bacterial neuraminidase, which removes the IAV
receptor sialic acid from the cell surface (Fig. 7), or bafilomycin
A1 (Fig. S4B), which prevents acidification of late endosomes or
lysosomes, abolished colocalization of virions with acidic com-
partments. These data suggest that IFITM proteins do not
interfere with the access of virions to low pH compartments
necessary for fusion of IFITM-restricted viruses.
Discussion
IFITM proteins play critical roles in the intrinsic and interferon-
mediated control of IAV replication in human and murine cell
lines [1]. In contrast to retroviral restriction factors – for example
TRIM5a, APOBEC3G, or BST2/tetherin – they limit replication
at a step mediated by the viral entry protein, likely before or
during fusion of the viral and cellular membranes [23]. Although
initially identified by an siRNA screen for factors that modulate
IAV replication, they also inhibit an early step in the life-cycle of
several flaviviruses including dengue and West Nile viruses [1].
The entry processes of IAV and flaviviruses both require low
pH in an intracellular compartment to promote conformational
changes in their entry proteins (HA and E protein, respectively)
[6]. Here we investigate three viruses – two filoviruses and SARS-
CoV – that similarly require access to acidic compartments to
enter cells. However, unlike IAV and flaviviruses, activation of
viral entry proteins of these viruses is not directly mediated by
acidic pH; rather acidic pH is necessary to activate lysosomal
proteases, which in turn cleave and activate these entry proteins.
The MARV, EBOV, and SARS-CoV entry proteins each require
cathepsin L activity to mediate fusion [10,11,12,13]. In addition,
Figure 7. IFITM proteins do not interfere with virion access to acidic cellular compartments. Infectious influenza A/PR/8/34 (H1N1) virus
was labeled with Alexa 488-conjugated murine anti-NA (N1) IgG2a (NA-112-S2.4) at 4uC for 16 hours (green). Vero E6 cells transduced to express the
indicated IFITM proteins or with vector alone were spin-inoculated with labeled influenza A/PR/8/34 (H1N1) virus (M.O.I.=100) at 4uC, washed twice
with PBS, and incubated with medium containing 100 nM LysoTracker Red DND-99 (red), which labels low pH compartments, at 37uC for
100 minutes. Cells were then washed twice with PBS, fixed with formaldehyde, and imaged by confocal microscopy. Bottom panels show a control in
which Vero E6 cells transduced with vector alone were pretreated with 1 U/ml bacterial neuraminidase (NA) for 24 hours before influenza A/PR/8/34
(H1N1) virus infection. Leftmost figures show differential interference contrast (DIC) and rightmost figures show the merged images of labeled virions
and LysoTracker labeled cells.
doi:10.1371/journal.ppat.1001258.g007
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and flaviviruses, the entry processes of all three cathepsin-
dependent viruses are restricted by a range of human IFITM
proteins and by their mouse and chicken orthologs.
It is not yet clear how IFITM proteins restrict these viruses, but
this study considerably narrows the range of possible mechanisms.
First, the number and diversity of restricted viruses tends to
exclude mechanisms that might be unique to individual viruses.
We previously showed that IFITM proteins do not decrease cell-
surface expression of sialic acid, the primary attachment moiety
for IAV [1]. Similarly, IFITM proteins do not significantly alter
expression of the SARS-CoV receptor ACE2. Nor is it plausible
that there is a physical interaction between the entry proteins of
restricted viruses and the IFITM molecules, given the variation
among these entry proteins and the ease with which such a
mechanism might be evaded. However, all IFITM-restricted
viruses described to date require access to late endosomal or
lysosomal compartments. This observation raises the possibility
that IFITM proteins interfere with endosomal trafficking or,
alternatively, make these compartments unsuitable for fusion of
restricted viruses.
Our data provide clear support for a mechanism that operates
at a later stage in the endocytic pathway. Specifically, we
circumvented restriction by complementing the cathepsin L
requirement of SARS-CoV with exogenous trypsin, thereby
promoting fusion at or near the plasma membrane. Moreover,
we do not observe any IFITM-induced differences in the efficiency
with which virions can access acidic compartments in the cell.
Therefore, when viruses are restricted, they are restricted in a late
endosomal or lysosomal compartment. We did not, however,
observe a loss of cathepsin activity in IFITM-expressing cells,
suggesting that this activity and the acidification that it requires are
not grossly impaired by IFITM proteins. It is of course possible
that these observations reflect underlying limitations in our ability
to detect relevant differences. In particular, our ability to detect
IAV in acidic compartments of IFITM expressing cells does not
exclude the possibility that these compartments are distinct from
those where productive infection can occur. Nonetheless, our data
suggest that IFITM proteins inhibit viral entry by mediating a
change in the properties of late endosomes or lysosomes. Two
additional observations are consistent with this hypothesis. First, in
some cell lines, enlarged vesicles could be observed in IFITM-
expressing cells, although the scale of this enlargement did not
correlate with the efficiency of viral restriction. Second, IFITM3 in
particular colocalizes extensively with markers of late endosomes
and lysosomes, but poorly with a marker of early endosomes (Fig.
S5). Our ability to bypass IFITM restriction may also shed light on
the course of SARS-CoV infection in vivo. In particular, following
induction of an interferon response, replication of the virus is
likely to be localized to tissues – for example the gastrointestinal
and respiratory tracts – where trypsin-like proteases are abundant
[16].
We also observed that different IFITM proteins restricted IAV
and filoviruses with different efficiencies. In general, IFITM3 and
its murine ortholog more efficiently restricted IAV than cathepsin-
dependent viruses, as indicated by the marked increase in IAV
entry, but not that of SARS-CoV, EBOV, or MARV, when
endogenous IFITM3 was depleted in HeLa cells. In contrast,
when endogenous IFITM1 was depleted in K562 cells, more
efficient entry was observed for all IFITM-restricted viruses. Also,
murine Ifitm5 and Ifitm6, and chicken Ifitm5 efficiently restricted
entry mediated by both filovirus GP1,2 proteins, but had little or no
effect on IAV HA-mediated entry. Thus the pattern of basal or
interferon-induced expression of the IFITM proteins is likely to be
an independent determinant of viral tropism and pathogenesis in
vivo.
Materials and Methods
Cells
Human embryonic kidney 293T, human cervical carcinoma
HeLa, and African green monkey epithelial Vero and Vero E6
cells were maintained in Dulbecco’s minimal essential medium
(DMEM; Invitrogen). Human lung epithelial A549 and human
myelogenous leukemia K562 cells were grown in Roswell Park
Memorial Institute (RPMI) 1640 medium (Invitrogen) and in
Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen),
respectively. All media were supplemented with 10% fetal bovine
serum (FBS; Invitrogen), 100 U/ml penicillin, and 100 mg/ml
streptomycin (Invitrogen). A549 cells transduced with vector alone
or stably expressing IFITM proteins were selected with 3 mg/ml
puromycin (Invitrogen). Vero and Vero E6 cells transduced with
vector alone or stably expressing IFITM proteins were maintained
in growth medium supplemented with 4 mg/ml puromycin. HeLa
or K562 cells stably expressing a control shRNA or shRNA
targeting IFITM1, 2, 3, or 1/3 mRNA were also selected with
4 mg/ml puromycin. Human umbilical vein endothelial cells
(HUVEC, Lonza) were maintained in endothelial cell growth
medium-2 (EGM-2) supplemented with EGM-2 bulletkit (Lonza).
Plasmids and constructs
A DNA segment encoding the c-myc tag sequence and the AgeI
restriction enzyme site was introduced into the pQCXIP vector
(Clontech). Plasmids encoding various c-myc-tagged IFITM
proteins were constructed by polymerase chain reaction (PCR)
amplification of the coding regions of human IFITM1, 2, and 3,
and mouse Ifitm1, 2, 3, 6, and 7 genes using plasmids carrying
respective cDNA (Open Biosystems) as templates [1]. PCR
products were then digested and ligated into the AgeI/BamHI
restriction sites of the pQCXIP vector. Codon-optimized chicken
Ifitm1, and human, mouse, and chicken Ifitm5 genes were
synthesized (Genescript) and also cloned into the pQCXIP vector.
pRS vector-based control shRNA and shRNA constructs targeting
human IFITM1, 2, 3, or 1/3 mRNA were purchased from
OriGene. The sequences of the control 29-mer and those targeting
coding regions of IFITM1, 2, or 3 mRNA are as follows: IFITM1
– TGCACAAGGAGGAACATGAGGTGGCTGTG; IFITM2 –
CCGCAGCGAGACCTCCGTGCCTGACCATG; IFITM3 –
TCCTCATGACCATTCTGCTCATCGTCATC; IFITM1/3 –
TGAATCACACTGTCCAAACCTTCTTCTCT; and control –
GCACTACCAGAGCTAACTCAGATAGTACT.
Pseudotyped murine leukemia viruses (MLVs) for
transduction and infections assays
Plasmids and procedures used to generate pseudotyped MLV-
GFP have been previously described, as have the various viral entry
proteins used [18]. These entry proteins include influenza A virus
HA proteins from A/PR/8/34 (H1N1) (H1(PR)), A/Udorn/
72 (H3N2)(H3(Ud)), A/Thailand/2(SP-33)/2004(H5N1)(H5(Thai)),
and A/FPV/Rostock/34 (H7N1)(H7(FPV)), glycoproteins (GP1,2)
from Marburg virus Musoke (MARV) and Ebola virus Mayinga
(EBOV), glycoprotein (GPC) from Machupo virus Carvallo
(MACV), S protein from severe acute respiratory syndrome
coronavirus Tor2 (SARS-CoV), and glycoprotein (GP) from
amphotrophic MLV [18,19,20,21].
To produce transducing viruses, 293T cells plated at 70%
confluence in T75 culture flasks were transfected using the calcium
phosphate method with 10 mg plasmid encoding MACV GPC,
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pQCXIP-based plasmids encoding various human, mouse, or
chicken IFITM proteins or pRS-based plasmids encoding shRNA
targeting human IFITM1, 2, 3, or 1/3 mRNA. 48 hours after
transfection, culture supernatants were harvested and filtered
through a 0.45 mM syringe filter (Nalgene).
Cells were then transduced by incubating transducing viruses
mixed with 10 mg/ml of polybrene (Santa Cruz Biotechnology)
and centrifuged at 4uC for 30 minutes at 4,0006g. Transduced
cells were maintained in growth medium and employed for stable
cell line selection or infection 48 hours later. The procedures for
MLV-GFP pseudovirus infection were similar to that for
transduction, except that spin inoculation was used and polybrene
was not included. 48 hours after infection, infected cells were
fixed with 1% formaldehyde (Polysciences) and analyzed by flow
cytometry. To test the effect of type I interferon (IFN) on entry of
MLV-GFP pseudotyped with various viral entry proteins, HeLa
cells were treated with 5000 U/ml or 1000 U/ml human IFN-b
(Antigenix America) for 48 hours before pseudovirus infection.
Trypsin-bypass experiments were performed similarly, except that
following spin inoculation at 4uC cells were incubated with 5 mg/
ml trypsin or with PBS alone at 37uC for 13 minutes.
Infectious filovirus replication assays
Propagation of MARV (Ci67 variant), EBOV (Kikwit variant),
or EBOV-GFP (Mayinga variant) has been described [20,24]. For
filovirus infection, Vero E6 or A549 cells transduced to express
IFITM proteins or with vector alone were incubated with MARV
or with EBOV at a multiplicity of infection (MOI) of 1 or 15. The
inocula were removed 1 h later and cells were washed 3 times
with phosphate buffered saline (PBS). Culture supernatants were
harvested in TRIzol (Invitrogen) 72 hours after infection, and
virion yield was determined by quantitative reverse transcriptase-
PCR (qRT-PCR). In brief, total RNA from culture supernatants of
untreated cells (mock) or cells infected with MARV or EBOV was
prepared using the MagMax 96 RNA Extraction Kit (Ambion).
qRT-PCR assays were performed on an ABI PRISM 7900HT
sequence detection system with the RNA UltraSenseTM one-step
kit (Invitrogen) and TaqMan Probes (Applied Biosystems) accord-
ing to manufacturers’ instructions. The final concentrations used
in the 20-ml reaction mix contained 5 ml of RNA, 0.4 mM of each
primer, 0.2 mM probe, 4 mlo f5 6reaction mix, 0.4 ml of Rox, and
1 ml of enzyme mix. The reaction was run as follows: reverse
transcription at 50uC for 20 minutes; initial denaturation at 95uC
for 2 minutes; amplification for 40 cycles at 95uC for 15 seconds,
60uC for 30 seconds. Serial 10-fold dilutions of the assayed (10
2–
10
7 copies) virus were used as standards.
For imaging MARV infected cells, cells were fixed in 10%-
buffered formalin (Val Tech Diagnostics) for 72 h and stained for
high-content quantitative image-based analysis with a murine
monoclonal antibody against MARV GP1,2 (9G4), followed by
Alexa 488-conjugated goat anti-mouse IgG (Invitrogen). All
infected cells were stained with Hoechst 33342 and HCS
CellMask Red (Invitrogen). Images were acquired and analyzed
on an Opera confocal reader (model 3842-Quadruple Excitation
High Sensitivity (QEHS), Perkin Elmer), at two exposures using a
106air objective.
Infectious SARS-CoV replication assays
Propagation of SARS-CoV has been described [25]. Vero cells
sorted to express moderate levels of ACE2 were transduced to
express IFITM proteins or with vector alone were incubated with
SARS-CoV (Urbani strain) at a multiplicity of infection (MOI) of
0.1 for 1 hour. 1, 6, 12, 18, 24, or 30 hours after infection, viral
titer was determined by plaque assay [25].
Immunofluorescence studies
ACE2 cell surface expression was measured by labeling cells
with 20 mg/ml Alexa-488 or Alexa-649 (Pierce) conjugated S
protein receptor-binding domain (RBD) of SARS-CoV for one
hour [26]. Cells were then washed 3 times with PBS, fixed with
1% formaldehyde and analyzed by flow cytometry. To image
pseudovirus infected cells, cells infected with various MLV-GFP
pseudotypes were fixed with 4% formaldehyde for 20 minutes,
permeablized with 0.2% Triton X-100 (Sigma) for 15 minutes,
and counterstained with 25 ng/ml 49,6-Diamidino-2-phenylindole
(DAPI; Sigma) for 5 minutes. Images were taken using the
Olympus IX51 fluorescence microscope and the DP controller
software (objective 206). Expression of human c-myc-tagged
IFITM proteins in A549 cells was assayed using similar
procedures. A549 cells transduced to express human IFITM
proteins or with vector alone were fixed, permeablized, labeled
with fluorescein isothiocyanate (FITC)-conjugated murine anti-c-
myc IgG (9E10; Abcam) for one hour, and counterstained with
DAPI. Cells were imaged using the same method.
Subcellular localization of human IFITM3 was measured by
confocal microscopy. IFITM3-expressing A549 cells were washed
twice with PBS and fixed in 50/50 acetone/methanol at 220uC
for 10 minutes. Fixed cells were then washed with PBS twice,
blocked with 10% goat serum in PBS for 30min, and labeled with
various primary antibodies for 2 hours. Primary antibodies used in
this study included murine anti-lysosomal-associated membrane
protein 1 (LAMP1, H4A3, 1:50 dilution; Santa Cruz Biotech)
IgG1, murine anti-LAMP2 (H4B4, 1:50 dilution; Santa Cruz
Biotech) IgG1, murine anti-CD63 (FC-5.01, 1:100 dilution;
Invitrogen) IgG2a, rabbit anti-early endosomal antigen 1 (EEA1,
1:100 dilution; Sigma) polyclonal antibody, and murine anti-c-myc
antibodies (9E10, 1:50 dilution, and 9E11, 1:900 dilution; Santa
Cruz Biotech). After primary antibody staining, cells were labeled
with goat Alexa 488- or 568- conjugated secondary antibodies
(1:500 dilution; Invitrogen) for 1 hour and then analyzed by
confocal microscopy using Leica TCS-SP1 laser confocal imaging
system (objective 1006).
Cathepsin activity assays
Cathepsin L activity was assayed using the cathepsin L activity
kit following the protocol provided by the manufacturer (EMD).
Cathepsin L activity of 2610
5 Vero E6 cells transduced to express
IFITM proteins or with vector alone was assayed. A cathepsin B
inhibitor (CA-074) was added in each tested sample to eliminate
the interference from cathepsin B. To evaluate cathepsin B or L
activities in live cells, Magic Red conjugated-(z-Leucine-Arginine)2
(MR-(RR)2), which binds to active cathepsin B, or MR
conjugated- (z-Phenylalanine-Arginine)2 (MR-(FR)2), which binds
to active cathepsin L, were used (Immunochemistry Technologies).
Vero E6 cells transduced to express IFITM proteins or with empty
vector were incubated with either MR-(RR)2 or MR-(FR)2 at
37uC. One hour later, cells were harvested, fixed with 1%
formaldehyde and analyzed by flow cytometry.
Western blots
Cells were lysed with either 1% Triton X-100 (Sigma) or 1%
NP-40 (Thermo Scientific). Protein samples were prepared in
reducing buffer and boiled for 5 minutes, analyzed by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE),
and transferred to a polyvinylidene difluoride membrane (Invitro-
gen). Expression of various c-myc-tagged IFITM proteins was
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(9E10; Santa Cruz Biotechnology). Endogenous IFITM protein
expression was probed by 0.4 mg/ml polyclonal rabbit anti-
IFITM1 (FL-125, Santa Cruz Biotechnology), rabbit anti-
IFITM2/3 (1:2000 dilution; anti-IFITM2 antibody was from
Proteintech Group which cross reacts to IFITM3 protein). b-actin
recognized by 1 mg/ml murine monoclonal anti-b-actin antibody
(Sigma) was used as a loading control.
Virion trafficking assays
Influenza A virus A/PR/8/34 was purchased from American
Type Culture Collection (ATCC) and was propagated in Madin-
Darby canine kidney (MDCK) cells as described [18]. To label
Influenza A/PR/8/34 virions, virions were incubated with 20 mg/
ml Alexa 488 (Pierce)-conjugated monoclonal murine anti-NA (N1)
IgG (NA-112-S2.4) at 4uC for 16 hours. (Antibody NA-112-S2.4
was generously provided by Dr. W. Gerhard, The Wistar Institute,
US). Virions were used for infection assays directly after labeling.
To monitor virion trafficking, Vero E6 cells transduced to
express IFITM proteins or with vector alone were incubated with
labeled influenza A/PR/8/34 virions at an MOI of 10 or 100 and
centrifuged at 4uC for 30 minutes at 40006g. Cells were then
washed three times with PBS and maintained in medium
containing 100 nM LysoTracker Red DND-99 (Invitrogen) at
37uC. 40, 70, or 100 minutes later, cells were fixed with 4%
formaldehyde and imaged with a Leica DMRBE Microscope and
Leica TCS-SP1 laser confocal imaging system (objective 1006).
Control cells were pre-treated with 1 U/ml neuraminidase from
Clostridium perfringens (Sigma) for 24 hours or with 100 nM
bafilomycin A1 (Baf A1, Sigma) for 6 hours before influenza A
virus infection.
Supporting Information
Figure S1 Viral infection and endogenous IFITM expression in
cells assayed. (A) A549 cells transduced to express indicated
IFITM proteins or with vector alone were infected with MLV-
GFP pseudotyped with MARV or EBOV glycoprotein as
indicated (green). Two days later, cells were fixed with
formaldehyde, permeablized by Triton X-100, and counterstained
with DAPI (blue). Images were taken using fluorescence
microscopy. (B) 293T, A549, or Vero E6 cells were treated with
5000 U/ml IFN-b, 250 ng/ml IFN-c, or with medium alone, as
indicated, for 48 hours. Expression of IFITM proteins was assayed
by western blot using the indicated anti-IFITM1 or anti-IFITM2/
3 antibody. (C) Vero E6 cells transduced to express indicated
IFITM proteins or with vector alone were incubated with live
MARV. 72 hours later cells were fixed with formaldehyde for
72 hours, labeled with murine monoclonal antibody against
MARV GP1,2 (9G4), counterstained with Hoechst 33342, and
imaged by confocal microscopy.
Found at: doi:10.1371/journal.ppat.1001258.s001 (3.61 MB TIF)
Figure S2 Pseudovirus entry, ACE2 and IFITM expression. (A)
Experiment similar to that in Fig. S1A except that control or
IFITM3 shRNA-expressing HeLa cells were infected with the
indicated pseudoviruses. (B) ACE2 expression in cells used in
Fig. 4D was assayed using Alexa 649-conjugated S protein RBD of
SARS-CoV, analyzed by flow cytometry, and shown as mean
fluorescence intensity. (C) ACE2 expression in cells used in Fig. 4G
was assayed by the same method described in (B). (D) A549 cells
transduced to express c-myc-tagged human IFITM2, IFITM5, or
with vector alone were fixed, permeablized, and stained with
FITC-conjugated anti-c-myc antibody (green). Cells were then
counterstained with DAPI (blue) and imaged using fluorescence
microscopy.
Found at: doi:10.1371/journal.ppat.1001258.s002 (3.19 MB TIF)
Figure S3 Alignment of IFITM orthologs used in this study. (A)
A representation of the topology of the IFITM proteins embedded
in a cellular membrane. (B) An alignment of human, mouse, and
chicken IFITM orthologs, with topological features indicated
above. Red indicates conserved residues.
Found at: doi:10.1371/journal.ppat.1001258.s003 (1.01 MB TIF)
Figure S4 IFITM proteins do not interfere with virion access to
acidic cellular compartments. (A) Experiment similar to that in
Fig. 7, except that Vero E6 cells transduced to express IFITM3 or
with vector alone were infected with labeled influenza A/PR/8/
34 virus at a MOI of 10. Infected cells were washed twice with
PBS, fixed with formaldehyde 40, 70, or 100 minutes as indicated
after incubation with labeled viruses. Leftmost figures show DIC
images and rightmost figures show merged images of labeled
virions and LysoTracker labeled cells. (B) Two different controls
for (A) are shown. Vero E6 cells transduced with vector alone were
pretreated with 100 nM bafilomycin A1 (BafA1) for 6 hours or
with 1 U/ml bacterial neuraminidase (NA) for 24 hours before
incubation with influenza A/PR/8/34 (H1N1) virus. Images were
taken by confocal microscopy 100 minutes later.
Found at: doi:10.1371/journal.ppat.1001258.s004 (8.16 MB TIF)
Figure S5 IFITM3 colocalizes to late endosomal lysosomal
markers. A549 cells expressing c-myc-tagged IFITM3 were fixed
with formaldehyde, permeablized, and labeled with the anti-c-myc
antibody and antibodies against indicated organelle markers. Cells
were then imaged by confocal microscopy. Leftmost figures show
DIC images and rightmost figures show merged images of
IFITM3 (red) and the indicated organelle markers (green).
Found at: doi:10.1371/journal.ppat.1001258.s005 (3.57 MB TIF)
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